GSK lifts long-term sales targets on new drug pipeline

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

GSK lifts long-term sales targets on new drug pipeline

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024.

GSK tells Labour to back British firms after Astra bust-up

The boss of pharma giant GSK has said the UK government must "step up" to stop Britain's drugs industry being overtaken by foreign rivals, writes Calum Muirhead. Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing business in the UK. It comes after AstraZeneca scrapped plans for a £450m vaccine factory near Liverpool following a row with Labour over State support. In a sign…

GSK sees annual profit slide on Zantac drug fallout

British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug. The company upgraded its outlook, however, on booming sales of cancer medicines. Profit after tax dropped to £2.6 billion ($3.3 billion) last year compared with net profit of £4.9 billion in 2023, GSK said in a statement. Turnover increased three percent to £31.4 billion, boosted by the succ…

GSK shares leap 5% as results top forecasts and guidance is upgraded! Can they keep rising?

GSK (LSE:GSK) shares ended 2024 on a sour note after what proved to be a rollercoaster year. The pharma giant dropped 7% over the 12 months, as worries over Zantac litigation and potential shake-ups in US healthcare policy shook investor confidence. Yet the underlying health of the FTSE 100 firm has remained steadfast, as illustrated by impressive full-year results released today (5 February). GSK’s share price has spiked 5% following the news. …

GSK hiked 2031 sales forecast to more than £40bn after 'excellent'

The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth quarter earnings.